SEC Form 4 · accession 0000899243-16-021028
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Healy
Director
Period of report
May 24, 2016
Accepted (ET)
May 26, 2016 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | holding | — | — | — | 92 | D | ||
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 2,893,221 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $18.28 | May 24, 2016 | A | 10,000 | A | — | May 24, 2026 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.
- F2The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 24, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.